KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Investments in Property, Plant, and Equipment

Last Annual Value

-200.00K

3-Year CAGR

%

5-Year CAGR

3%

10-Year CAGR

2%

KT

Kalaris Therapeutics Inc Competitors Analysis of Investments in Property, Plant, and Equipment

KLRS · NASDAQ
CompanyInvestments in Property, Plant, and Equipment
CAGR 3Y
CAGR 5Y
CAGR 10Y
-200.00K
N/AN/AN/A 
0.00
N/AN/AN/A
-2.59M
N/AN/AN/A
-71.00K
N/AN/AN/A
-33.95K
N/AN/AN/A
-574.00K
N/AN/AN/A
-388.00K
N/AN/AN/A
-212.00K
N/AN/AN/A
-557.00K
N/AN/AN/A
0.00
N/AN/AN/A
-1.93M
N/AN/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7